A senolytic RCT in MASH, an AMPK activator that stops at the worm, and proteomic clocks meet their first trial
The most clinically relevant item is the first randomized, placebo-controlled dasatinib+quercetin trial in biopsy-proven MASH: a 40-point absolute difference in fibrosis improvement on biopsy, but n=31, an unbalanced randomization, a risk-ratio CI that crosses 1, and no difference on non-invasive fibrosis tests; the authors themselves call it hypothesis-generating. Mechanistically, a new Nature Aging paper ties senescent-cell persistence to chaperone-mediated autophagy failure in macrophages, while a bioRxiv preprint proposes a transitional senescence-like state behind inflammatory monocyte expansion. On the translational-caution side, the direct AMPK activator 991 extends lifespan in yeast, worms and flies but has not shown lifespan extension in mice, and higher doses shortened life.
Fibrosis improvement on biopsy, D+Q vs placebo in MASH (8/17 vs 1/14; RR 6.59, 95% CI 0.93–46.5; n=31, hypothesis-generating)
Where the human evidence is
Count by statusEvidence-stage map
Evidence stage × investigator promise (1–10)Senescence mechanisms: clearance failure and immune aging
Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells
CMA-deficient cells still become senescent but acquire features of aged senescent cells; their SASP suppresses CMA in macrophages and impairs engulfment of senescent cells. Macrophage-specific CMA blockade increased senescent-cell accumulation and slowed resolution in wound healing in mice, while pharmacological CMA activation reduced senescent burden in aged mice and severity in a pulmonary fibrosis model. Supports a clearance-failure (rather than purely production) model of senescent-cell accumulation. Evidence is cell and mouse only; compounds and effect sizes were not verified from the primary text.
Read the paperA transitional senescence program drives inflammatory monocyte state expansion in aging humans
Rutgers group combined SA-bGal sorting with bulk and single-cell multiomics of human monocytes (flow n=66 young/180 older; single-cell multiome only 4 young/3 older donors, 8,758 cells). They propose a transient senescence-like bridge from classical monocytes to an inflammatory state, AP-1-driven on a pre-existing ETS/MEF/AP-1 network, with older-donor monocytes ~2.2-fold enriched in a sepsis-associated MS1 state. Trajectory inference and sepsis links are correlative; AP-1 as a target was not tested experimentally in the portions reviewed.
Read the paperBiomarkers: clocks in trials, lipid-length aging
Proteomic aging clocks go to trial: six clocks deployed as readouts in a randomized intervention study (commentary)
Robertson and Chandra (Mayo) comment on a report in which six proteomic clocks were used together as trial readouts; per secondary coverage the exercise revealed more about the clocks (convergence, divergence, reliability) than about the tested drug. The intervention, sample size and effect sizes could not be verified, so no efficacy claim should be drawn. Regulatory commentary notes proteomic age scores have no established surrogate-endpoint standing.
Read the paperLonger lipids mark aging and constrain lifespan
Multi-tissue lipidomics across mice, C. elegans, flies and humans reports a shift toward longer lipid chains with age (also in human heart disease progression), shorter species in dietary-restricted mouse heart, and Plb1 (lipid remodelling) correlating with mouse lifespan and genetically linked to human frailty. Reducing Plb1 reversed lipid elongation and extended C. elegans lifespan in a length-dependent manner. Lifespan causality is shown only in worms; human interventional relevance is untested. Details are from a news report; primary text not reviewed.
Read the paper